Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Davison

Showing results (371-380 of 451) with videos related to

Pageof 46
Sort By:
JACC. Heart Failure|April 4, 2016
Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF TrialPeter S Pang, John R Teerlink, Adriaan A Voors, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 3, 2017
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
European Journal of Heart Failure|June 1, 2017
Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) studyJohn R Teerlink, Marco Metra, Gerasimos S Filippatos, et al.
JACC. Heart Failure|May 9, 2015
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF StudiesBeth A Davison, Marco Metra, Gad Cotter, et al.
European Journal of Heart Failure|May 22, 2016
Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF)Karen Sliwa, Albertino Damasceno, Beth A Davison, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2020
Chromosome-free bacterial cells are safe and programmable platforms for synthetic biologyCatherine Fan, Paul A Davison, Robert Habgood, et al.
American Heart Journal|April 30, 2017
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trialPeter S Pang, John R Teerlink, Leandro Boer-Martins, et al.
European Journal of Heart Failure|April 29, 2017
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 studyJohn R Teerlink, Adriaan A Voors, Piotr Ponikowski, et al.
European Heart Journal|March 11, 2011
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT StudyMarco Metra, Christopher M O'Connor, Beth A Davison, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 19, 2023
Disconnect between the effects of serelaxin on renal function and outcome in acute heart failureI E Beldhuis, J M Ter Maaten, S M Figarska, et al.
Pageof 46

Showing results (371-380 of 451) with videos related to

Sort By:
Pageof 46
JACC. Heart Failure|April 4, 2016
Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF TrialPeter S Pang, John R Teerlink, Adriaan A Voors, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 3, 2017
Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trialGerasimos Filippatos, Dimitrios Farmakis, Marco Metra, et al.
European Journal of Heart Failure|June 1, 2017
Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) studyJohn R Teerlink, Marco Metra, Gerasimos S Filippatos, et al.
JACC. Heart Failure|May 9, 2015
Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF StudiesBeth A Davison, Marco Metra, Gad Cotter, et al.
European Journal of Heart Failure|May 22, 2016
Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF)Karen Sliwa, Albertino Damasceno, Beth A Davison, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 8, 2020
Chromosome-free bacterial cells are safe and programmable platforms for synthetic biologyCatherine Fan, Paul A Davison, Robert Habgood, et al.
American Heart Journal|April 30, 2017
Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trialPeter S Pang, John R Teerlink, Leandro Boer-Martins, et al.
European Journal of Heart Failure|April 29, 2017
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 studyJohn R Teerlink, Adriaan A Voors, Piotr Ponikowski, et al.
European Heart Journal|March 11, 2011
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT StudyMarco Metra, Christopher M O'Connor, Beth A Davison, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 19, 2023
Disconnect between the effects of serelaxin on renal function and outcome in acute heart failureI E Beldhuis, J M Ter Maaten, S M Figarska, et al.
Pageof 46